Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $24

Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $21 to $24.